Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

Medicines360 · NCT07669935

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–99 · Women only
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
5500
US sites recruiting
1
Study start
September 8, 2026
Record last updated
September 30, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications [i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)] and risk of adverse outcomes.

Being studied: None (this is an observational study with no intervention)

Conditions: GDM; Preterm Preeclampsia; Preeclampsia; Fetal Growth Restriction (FGR); Pregnancy Complications

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥18 years
  • Nulliparous (no previous births ≥20wk GA)
  • Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0/7-17 6/7 weeks of gestation
  • Ability to consent and comply with study procedures and follow-up

Exclusion Criteria

  • Multiple gestation
  • Inability to provide blood
  • Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual
  • Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)
  • Current or recent (within two months) participation in an interventional clinical study.

Recruiting US locations

  • Woman's Hospital

    Baton Rouge, LA 70817

    Site contact: Elizabeth Sutton · 225-927-1300 · Elizabeth.Sutton@womans.org

Study contacts (from the official record)

  • Carrie Fralick, MS · 225-512-5546 · Carie.Fralick@womans.org
All pregnancy studies in Louisiana →
Advancing Stillbirth Prevention Through Innovative Risk Evaluation… (NCT07669935) | Bored Studies